Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 57 | 2022 | 4883 | 5.410 |
Why?
|
Cyclophosphamide | 27 | 2021 | 2207 | 4.340 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 10 | 2021 | 276 | 4.240 |
Why?
|
Graft vs Host Disease | 36 | 2022 | 2708 | 3.940 |
Why?
|
Leukemia, Myeloid, Acute | 27 | 2022 | 3027 | 3.470 |
Why?
|
Transplantation Conditioning | 25 | 2021 | 1514 | 3.080 |
Why?
|
Killer Cells, Natural | 16 | 2021 | 2191 | 2.260 |
Why?
|
Lymphocyte Depletion | 5 | 2020 | 652 | 1.840 |
Why?
|
Interleukin-15 | 5 | 2019 | 165 | 1.710 |
Why?
|
Hematologic Neoplasms | 12 | 2020 | 1556 | 1.600 |
Why?
|
Myelodysplastic Syndromes | 11 | 2021 | 1181 | 1.540 |
Why?
|
Cord Blood Stem Cell Transplantation | 5 | 2021 | 324 | 1.440 |
Why?
|
HLA Antigens | 8 | 2021 | 1717 | 1.430 |
Why?
|
Leukemia | 5 | 2021 | 1449 | 1.310 |
Why?
|
Tissue Donors | 8 | 2019 | 2035 | 1.220 |
Why?
|
Bone Marrow Diseases | 2 | 2017 | 244 | 1.100 |
Why?
|
Histocompatibility | 5 | 2019 | 378 | 1.070 |
Why?
|
Granulocyte Colony-Stimulating Factor | 4 | 2021 | 623 | 1.050 |
Why?
|
Myeloablative Agonists | 4 | 2019 | 223 | 0.980 |
Why?
|
Transplantation, Homologous | 15 | 2021 | 4917 | 0.960 |
Why?
|
Receptors, IgG | 3 | 2015 | 613 | 0.950 |
Why?
|
Cytokines | 4 | 2021 | 7147 | 0.920 |
Why?
|
Lymphocyte Transfusion | 2 | 2020 | 247 | 0.830 |
Why?
|
Immunotherapy, Adoptive | 5 | 2021 | 869 | 0.820 |
Why?
|
Cytomegalovirus Infections | 5 | 2021 | 721 | 0.820 |
Why?
|
Opportunistic Infections | 3 | 2017 | 388 | 0.710 |
Why?
|
Hematopoietic Stem Cell Mobilization | 3 | 2021 | 227 | 0.700 |
Why?
|
Cytomegalovirus | 3 | 2021 | 656 | 0.680 |
Why?
|
Tongue Diseases | 1 | 2017 | 71 | 0.650 |
Why?
|
Sarcoma, Myeloid | 1 | 2017 | 55 | 0.650 |
Why?
|
Epitopes | 3 | 2020 | 2716 | 0.630 |
Why?
|
Immunologic Memory | 4 | 2021 | 1403 | 0.610 |
Why?
|
Salvage Therapy | 4 | 2021 | 1311 | 0.580 |
Why?
|
Azacitidine | 4 | 2021 | 291 | 0.550 |
Why?
|
Lymphocyte Subsets | 1 | 2015 | 337 | 0.540 |
Why?
|
Tongue | 1 | 2017 | 404 | 0.520 |
Why?
|
T-Lymphocytes | 8 | 2021 | 10329 | 0.520 |
Why?
|
Acetates | 1 | 2014 | 306 | 0.500 |
Why?
|
Leukemia, Myeloid | 1 | 2016 | 742 | 0.500 |
Why?
|
Serum Albumin | 1 | 2016 | 688 | 0.500 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2017 | 634 | 0.480 |
Why?
|
Disease-Free Survival | 12 | 2021 | 7195 | 0.460 |
Why?
|
Virus Activation | 1 | 2013 | 325 | 0.450 |
Why?
|
Hematologic Diseases | 1 | 2015 | 484 | 0.440 |
Why?
|
ADAM Proteins | 1 | 2013 | 274 | 0.440 |
Why?
|
Aged | 43 | 2021 | 162271 | 0.440 |
Why?
|
Mesenchymal Stem Cell Transplantation | 1 | 2015 | 465 | 0.430 |
Why?
|
ABO Blood-Group System | 1 | 2013 | 356 | 0.420 |
Why?
|
Siblings | 7 | 2021 | 818 | 0.420 |
Why?
|
Immunophenotyping | 1 | 2015 | 1915 | 0.410 |
Why?
|
Middle Aged | 48 | 2021 | 216468 | 0.410 |
Why?
|
Humans | 92 | 2022 | 686663 | 0.410 |
Why?
|
Young Adult | 27 | 2021 | 56052 | 0.400 |
Why?
|
Adult | 50 | 2021 | 211400 | 0.400 |
Why?
|
Histocompatibility Testing | 4 | 2020 | 832 | 0.400 |
Why?
|
Immunocompromised Host | 2 | 2017 | 889 | 0.390 |
Why?
|
Encephalitis, Herpes Simplex | 1 | 2009 | 61 | 0.380 |
Why?
|
Neoplasms | 4 | 2021 | 19538 | 0.380 |
Why?
|
Lymphocyte Activation | 4 | 2014 | 5989 | 0.380 |
Why?
|
Hepatic Veno-Occlusive Disease | 2 | 2022 | 220 | 0.370 |
Why?
|
Retrospective Studies | 30 | 2022 | 67320 | 0.370 |
Why?
|
Remission Induction | 4 | 2019 | 2387 | 0.370 |
Why?
|
Lymphoma | 1 | 2017 | 1863 | 0.350 |
Why?
|
Quinazolines | 1 | 2014 | 1418 | 0.330 |
Why?
|
Survival Rate | 11 | 2021 | 13606 | 0.330 |
Why?
|
Health Personnel | 1 | 2020 | 2837 | 0.330 |
Why?
|
Bone Marrow Cells | 1 | 2015 | 2698 | 0.320 |
Why?
|
Peptides | 1 | 2019 | 4537 | 0.320 |
Why?
|
Immunosuppressive Agents | 7 | 2021 | 4208 | 0.310 |
Why?
|
Cardiomyopathies | 1 | 2017 | 1696 | 0.300 |
Why?
|
Proteins | 3 | 2018 | 6264 | 0.300 |
Why?
|
Interferon-gamma | 3 | 2015 | 3263 | 0.300 |
Why?
|
Liver Transplantation | 1 | 2016 | 1958 | 0.290 |
Why?
|
Virus Diseases | 3 | 2021 | 649 | 0.290 |
Why?
|
Male | 42 | 2021 | 352465 | 0.290 |
Why?
|
Antimetabolites, Antineoplastic | 3 | 2021 | 677 | 0.290 |
Why?
|
Recurrence | 6 | 2020 | 8198 | 0.290 |
Why?
|
Antiviral Agents | 2 | 2014 | 2625 | 0.270 |
Why?
|
Registries | 2 | 2019 | 8033 | 0.260 |
Why?
|
Physicians | 1 | 2020 | 4060 | 0.260 |
Why?
|
Adolescent | 21 | 2021 | 84957 | 0.260 |
Why?
|
Female | 41 | 2021 | 375459 | 0.260 |
Why?
|
K562 Cells | 3 | 2017 | 662 | 0.250 |
Why?
|
Multiple Myeloma | 2 | 2017 | 4844 | 0.240 |
Why?
|
Acute Disease | 5 | 2021 | 7202 | 0.240 |
Why?
|
Graft Survival | 3 | 2018 | 3766 | 0.230 |
Why?
|
Survival Analysis | 6 | 2019 | 10766 | 0.230 |
Why?
|
Haplotypes | 3 | 2017 | 2913 | 0.220 |
Why?
|
Herpesviridae | 1 | 2021 | 107 | 0.220 |
Why?
|
Cytotoxicity, Immunologic | 3 | 2021 | 1577 | 0.220 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 1307 | 0.220 |
Why?
|
Chimerism | 1 | 2021 | 139 | 0.210 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2021 | 5265 | 0.210 |
Why?
|
Single-Chain Antibodies | 1 | 2020 | 110 | 0.210 |
Why?
|
Heterocyclic Compounds | 1 | 2021 | 279 | 0.200 |
Why?
|
BK Virus | 1 | 2020 | 132 | 0.190 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2018 | 8610 | 0.190 |
Why?
|
Adoptive Transfer | 3 | 2016 | 882 | 0.190 |
Why?
|
Bone Marrow | 3 | 2019 | 2901 | 0.180 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2017 | 1394 | 0.180 |
Why?
|
Graft vs Leukemia Effect | 2 | 2020 | 113 | 0.180 |
Why?
|
Dermatitis | 1 | 2019 | 193 | 0.180 |
Why?
|
Blood Donors | 2 | 2019 | 354 | 0.180 |
Why?
|
Ustilaginales | 1 | 2017 | 1 | 0.170 |
Why?
|
Community-Acquired Infections | 1 | 2021 | 460 | 0.170 |
Why?
|
Natural Killer T-Cells | 1 | 2021 | 308 | 0.170 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2020 | 4115 | 0.170 |
Why?
|
Transplantation, Autologous | 2 | 2021 | 2072 | 0.170 |
Why?
|
Fungemia | 1 | 2017 | 46 | 0.170 |
Why?
|
Dermatomycoses | 1 | 2017 | 46 | 0.170 |
Why?
|
Receptors, Natural Killer Cell | 1 | 2016 | 58 | 0.170 |
Why?
|
Antineoplastic Agents | 2 | 2018 | 13898 | 0.170 |
Why?
|
Patient Care Management | 1 | 2020 | 324 | 0.160 |
Why?
|
Genes, Neoplasm | 1 | 2019 | 402 | 0.160 |
Why?
|
Viremia | 2 | 2016 | 684 | 0.160 |
Why?
|
Lymphoproliferative Disorders | 1 | 2020 | 542 | 0.160 |
Why?
|
Nitriles | 1 | 2021 | 958 | 0.150 |
Why?
|
Yeasts | 1 | 2017 | 300 | 0.150 |
Why?
|
Lymphoma, T-Cell | 1 | 2019 | 319 | 0.150 |
Why?
|
Janus Kinase 1 | 1 | 2015 | 100 | 0.150 |
Why?
|
Premedication | 1 | 2016 | 275 | 0.150 |
Why?
|
Recombinant Fusion Proteins | 4 | 2018 | 3983 | 0.150 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2017 | 232 | 0.150 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2021 | 8895 | 0.150 |
Why?
|
Mucositis | 1 | 2016 | 92 | 0.150 |
Why?
|
Bone Marrow Transplantation | 3 | 2021 | 2880 | 0.150 |
Why?
|
Anemia, Aplastic | 1 | 2017 | 225 | 0.150 |
Why?
|
Treatment Outcome | 8 | 2021 | 60991 | 0.150 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2020 | 497 | 0.140 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2017 | 335 | 0.140 |
Why?
|
Immunotherapy | 3 | 2021 | 3793 | 0.140 |
Why?
|
Interleukin-18 | 2 | 2014 | 220 | 0.140 |
Why?
|
Cytokine-Induced Killer Cells | 1 | 2014 | 5 | 0.140 |
Why?
|
Proportional Hazards Models | 3 | 2021 | 12525 | 0.140 |
Why?
|
Heart Failure | 1 | 2017 | 9179 | 0.140 |
Why?
|
Primary Myelofibrosis | 1 | 2015 | 177 | 0.140 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2021 | 3881 | 0.130 |
Why?
|
Respiratory Tract Infections | 1 | 2021 | 930 | 0.130 |
Why?
|
Heparin | 1 | 2021 | 1679 | 0.130 |
Why?
|
Exanthema | 1 | 2017 | 434 | 0.130 |
Why?
|
Ligands | 2 | 2019 | 3189 | 0.130 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily D | 1 | 2012 | 33 | 0.130 |
Why?
|
Receptors, Interleukin-12 | 1 | 2012 | 33 | 0.130 |
Why?
|
Isoantibodies | 1 | 2017 | 669 | 0.130 |
Why?
|
Interleukin-12 | 2 | 2014 | 601 | 0.130 |
Why?
|
Receptors, Interleukin-18 | 1 | 2012 | 27 | 0.130 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily C | 1 | 2012 | 33 | 0.130 |
Why?
|
Piperidines | 1 | 2021 | 1512 | 0.130 |
Why?
|
Necrosis | 1 | 2017 | 1664 | 0.120 |
Why?
|
L-Selectin | 1 | 2013 | 236 | 0.120 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 1252 | 0.120 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 311 | 0.120 |
Why?
|
Antifungal Agents | 1 | 2017 | 680 | 0.120 |
Why?
|
Janus Kinase 2 | 1 | 2015 | 505 | 0.120 |
Why?
|
Receptors, Interleukin-2 | 1 | 2014 | 627 | 0.120 |
Why?
|
Adipocytes | 1 | 2019 | 1204 | 0.110 |
Why?
|
Netherlands | 1 | 2016 | 2041 | 0.110 |
Why?
|
Myeloproliferative Disorders | 1 | 2017 | 513 | 0.110 |
Why?
|
GPI-Linked Proteins | 1 | 2013 | 509 | 0.110 |
Why?
|
Hodgkin Disease | 1 | 2019 | 1428 | 0.110 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 15407 | 0.110 |
Why?
|
Propensity Score | 1 | 2018 | 1751 | 0.110 |
Why?
|
Age Factors | 3 | 2018 | 19295 | 0.110 |
Why?
|
Pyrazoles | 1 | 2021 | 1907 | 0.110 |
Why?
|
Transplantation Immunology | 1 | 2013 | 630 | 0.110 |
Why?
|
Immunity, Innate | 2 | 2020 | 2892 | 0.100 |
Why?
|
Syndrome | 1 | 2016 | 3178 | 0.100 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 2012 | 1039 | 0.100 |
Why?
|
Cell Proliferation | 3 | 2016 | 10990 | 0.100 |
Why?
|
Lymphoma, B-Cell | 1 | 2015 | 900 | 0.100 |
Why?
|
Lectins, C-Type | 1 | 2012 | 617 | 0.090 |
Why?
|
Incidence | 7 | 2021 | 20496 | 0.090 |
Why?
|
Pyrimidines | 1 | 2021 | 2909 | 0.090 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2017 | 1456 | 0.090 |
Why?
|
Mice, Inbred NOD | 3 | 2021 | 1974 | 0.090 |
Why?
|
Vidarabine | 2 | 2021 | 348 | 0.090 |
Why?
|
Bacterial Infections | 1 | 2016 | 1437 | 0.090 |
Why?
|
DNA Methylation | 1 | 2021 | 3987 | 0.080 |
Why?
|
Benzimidazoles | 1 | 2013 | 883 | 0.080 |
Why?
|
Mice | 6 | 2021 | 80803 | 0.080 |
Why?
|
Secondary Prevention | 1 | 2013 | 1493 | 0.080 |
Why?
|
Protein Transport | 1 | 2013 | 2101 | 0.080 |
Why?
|
Neutrophils | 1 | 2020 | 3876 | 0.080 |
Why?
|
Donor Selection | 2 | 2019 | 174 | 0.080 |
Why?
|
Interleukin-6 | 1 | 2016 | 3105 | 0.080 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2016 | 2912 | 0.080 |
Why?
|
Macrophages | 1 | 2021 | 5748 | 0.070 |
Why?
|
Simplexvirus | 1 | 2009 | 828 | 0.070 |
Why?
|
Cytarabine | 2 | 2017 | 683 | 0.070 |
Why?
|
Nuclear Proteins | 1 | 2020 | 6009 | 0.070 |
Why?
|
Risk | 2 | 2016 | 9915 | 0.070 |
Why?
|
Stroke Volume | 1 | 2017 | 4070 | 0.070 |
Why?
|
Chronic Disease | 4 | 2021 | 8882 | 0.070 |
Why?
|
Protein Processing, Post-Translational | 1 | 2013 | 2111 | 0.070 |
Why?
|
Animals | 8 | 2021 | 170849 | 0.070 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 5114 | 0.070 |
Why?
|
Echocardiography | 1 | 2017 | 5097 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 6970 | 0.070 |
Why?
|
Peptide Fragments | 1 | 2017 | 5167 | 0.070 |
Why?
|
Risk Factors | 5 | 2020 | 69278 | 0.060 |
Why?
|
Time Factors | 3 | 2017 | 42271 | 0.060 |
Why?
|
Cell Membrane | 1 | 2013 | 3982 | 0.060 |
Why?
|
Neoplasm, Residual | 2 | 2018 | 932 | 0.060 |
Why?
|
Follow-Up Studies | 4 | 2021 | 39737 | 0.060 |
Why?
|
Cells, Cultured | 3 | 2014 | 20620 | 0.060 |
Why?
|
Comorbidity | 1 | 2017 | 10648 | 0.060 |
Why?
|
Cytotoxicity Tests, Immunologic | 1 | 2021 | 453 | 0.060 |
Why?
|
Flow Cytometry | 1 | 2012 | 6230 | 0.060 |
Why?
|
Busulfan | 1 | 2021 | 260 | 0.050 |
Why?
|
Cohort Studies | 2 | 2015 | 38732 | 0.050 |
Why?
|
Enzyme Inhibitors | 1 | 2013 | 3998 | 0.050 |
Why?
|
Polydeoxyribonucleotides | 1 | 2022 | 120 | 0.050 |
Why?
|
Antigens, CD | 1 | 2012 | 4256 | 0.050 |
Why?
|
Ohio | 1 | 2021 | 360 | 0.050 |
Why?
|
Consensus | 2 | 2019 | 2434 | 0.050 |
Why?
|
HLA-A2 Antigen | 1 | 2020 | 249 | 0.050 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 15075 | 0.050 |
Why?
|
Benzylamines | 1 | 2021 | 233 | 0.050 |
Why?
|
Mice, SCID | 2 | 2017 | 2913 | 0.050 |
Why?
|
Fever | 2 | 2017 | 1565 | 0.050 |
Why?
|
Drug Therapy, Combination | 2 | 2021 | 6632 | 0.050 |
Why?
|
Child | 5 | 2021 | 71361 | 0.050 |
Why?
|
Receptors, KIR | 1 | 2019 | 124 | 0.050 |
Why?
|
Chemokine CXCL12 | 1 | 2021 | 468 | 0.050 |
Why?
|
Child, Preschool | 3 | 2021 | 41159 | 0.050 |
Why?
|
Multivariate Analysis | 1 | 2013 | 12734 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 1 | 2015 | 5252 | 0.050 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 916 | 0.050 |
Why?
|
Missouri | 1 | 2017 | 113 | 0.040 |
Why?
|
Cladribine | 1 | 2017 | 28 | 0.040 |
Why?
|
Cell Line, Tumor | 3 | 2021 | 17251 | 0.040 |
Why?
|
Trichosporon | 1 | 2017 | 11 | 0.040 |
Why?
|
MicroRNAs | 1 | 2013 | 3587 | 0.040 |
Why?
|
Reproducibility of Results | 1 | 2016 | 19308 | 0.040 |
Why?
|
Idarubicin | 1 | 2017 | 62 | 0.040 |
Why?
|
Gene Expression Regulation | 2 | 2014 | 12680 | 0.040 |
Why?
|
Filgrastim | 1 | 2017 | 142 | 0.040 |
Why?
|
Mitoxantrone | 1 | 2017 | 158 | 0.040 |
Why?
|
Cryptococcus | 1 | 2017 | 30 | 0.040 |
Why?
|
Echinocandins | 1 | 2017 | 42 | 0.040 |
Why?
|
Cryopreservation | 1 | 2021 | 621 | 0.040 |
Why?
|
Saccharomyces | 1 | 2017 | 66 | 0.040 |
Why?
|
Lipopeptides | 1 | 2017 | 88 | 0.040 |
Why?
|
Amphotericin B | 1 | 2017 | 146 | 0.040 |
Why?
|
Nuclear Family | 1 | 2018 | 325 | 0.040 |
Why?
|
Living Donors | 1 | 2021 | 565 | 0.040 |
Why?
|
Cell Degranulation | 1 | 2017 | 301 | 0.040 |
Why?
|
Chromatin Assembly and Disassembly | 1 | 2021 | 634 | 0.040 |
Why?
|
Aged, 80 and over | 5 | 2021 | 59331 | 0.040 |
Why?
|
Graft Rejection | 2 | 2021 | 4314 | 0.040 |
Why?
|
Steroids | 1 | 2021 | 830 | 0.040 |
Why?
|
5-Methylcytosine | 1 | 2016 | 159 | 0.040 |
Why?
|
Receptors, CXCR4 | 1 | 2021 | 737 | 0.040 |
Why?
|
Adenine | 1 | 2021 | 894 | 0.040 |
Why?
|
Signal Transduction | 3 | 2017 | 24351 | 0.040 |
Why?
|
Etoposide | 1 | 2017 | 632 | 0.040 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2021 | 761 | 0.040 |
Why?
|
Perforin | 1 | 2015 | 174 | 0.040 |
Why?
|
Drug Evaluation | 1 | 2016 | 688 | 0.040 |
Why?
|
Drug Resistance | 1 | 2021 | 1617 | 0.040 |
Why?
|
Mycoses | 1 | 2017 | 364 | 0.030 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2015 | 331 | 0.030 |
Why?
|
Electroencephalography | 1 | 2009 | 5579 | 0.030 |
Why?
|
Granzymes | 1 | 2015 | 272 | 0.030 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2021 | 1536 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 2020 | 1221 | 0.030 |
Why?
|
Specific Pathogen-Free Organisms | 1 | 2013 | 242 | 0.030 |
Why?
|
Gastrointestinal Tract | 1 | 2020 | 845 | 0.030 |
Why?
|
Fetal Blood | 1 | 2020 | 1370 | 0.030 |
Why?
|
Coculture Techniques | 1 | 2017 | 1393 | 0.030 |
Why?
|
Neutropenia | 1 | 2017 | 852 | 0.030 |
Why?
|
Integrins | 1 | 2017 | 884 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2017 | 2296 | 0.030 |
Why?
|
Calcineurin | 1 | 2013 | 230 | 0.030 |
Why?
|
STAT5 Transcription Factor | 1 | 2014 | 303 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2020 | 2176 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2017 | 13413 | 0.030 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 675 | 0.030 |
Why?
|
Sulfonamides | 1 | 2021 | 1961 | 0.030 |
Why?
|
Mutation | 1 | 2016 | 28848 | 0.030 |
Why?
|
Prospective Studies | 3 | 2021 | 49071 | 0.030 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 1809 | 0.030 |
Why?
|
Infant | 1 | 2013 | 33918 | 0.030 |
Why?
|
Models, Immunological | 1 | 2013 | 542 | 0.030 |
Why?
|
Lymphocytes | 1 | 2019 | 2867 | 0.030 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2021 | 3053 | 0.030 |
Why?
|
Drug Synergism | 1 | 2015 | 1939 | 0.030 |
Why?
|
Lentivirus | 1 | 2013 | 536 | 0.030 |
Why?
|
Vaccination | 1 | 2022 | 2487 | 0.030 |
Why?
|
Transduction, Genetic | 1 | 2013 | 994 | 0.030 |
Why?
|
Prognosis | 2 | 2021 | 28923 | 0.020 |
Why?
|
Genes, Reporter | 1 | 2013 | 1659 | 0.020 |
Why?
|
Interleukins | 1 | 2013 | 832 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2017 | 5182 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 7791 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2020 | 18495 | 0.020 |
Why?
|
Mice, Knockout | 2 | 2015 | 15597 | 0.020 |
Why?
|
Immunologic Factors | 1 | 2017 | 1477 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2014 | 2159 | 0.020 |
Why?
|
Genome, Human | 1 | 2021 | 4458 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8920 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2020 | 4355 | 0.020 |
Why?
|
Interleukin-2 | 1 | 2014 | 1981 | 0.020 |
Why?
|
Anticoagulants | 1 | 2021 | 4173 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 11115 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2013 | 1930 | 0.020 |
Why?
|
NF-kappa B | 1 | 2013 | 2553 | 0.020 |
Why?
|
African Americans | 1 | 2020 | 5144 | 0.020 |
Why?
|
Biopsy | 1 | 2017 | 6849 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 9114 | 0.020 |
Why?
|
Hematopoietic Stem Cells | 1 | 2017 | 3457 | 0.020 |
Why?
|
RNA Interference | 1 | 2013 | 3103 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2013 | 2833 | 0.020 |
Why?
|
Up-Regulation | 1 | 2013 | 4441 | 0.020 |
Why?
|
United States | 2 | 2021 | 65579 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2013 | 3628 | 0.020 |
Why?
|
Pandemics | 1 | 2021 | 5859 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2009 | 33186 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2019 | 16227 | 0.010 |
Why?
|
Disease Progression | 1 | 2015 | 13204 | 0.010 |
Why?
|
Risk Assessment | 1 | 2017 | 23739 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2013 | 23439 | 0.010 |
Why?
|